Microbiology International

800ezmicro.com

Microbiology International specializes in autoclaves, peristaltic pumps, air samplers, anaerobic chambers, plate pourers, media preparators and stomachers as well as other automation equipment used in microbiological laboratories. We also provide laboratories with the most innovative automation equipment as well as the highest quality rapid detection kits and consumable products for pathogen detection available worldwide. Our equipment quickly automates tedious, manual lab processes and when combined with our ability to provide customized culture media products, we are able to make your lab as efficient as possible.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

news image

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More

Cell and Gene Therapy

Q² SOLUTIONS LAUNCHES INNOVATIVE SELF-COLLECTION SAFETY LAB PANEL IN COLLABORATION WITH TASSO

Q² Solutions and IQVIA, Tasso | October 07, 2022

news image

Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory. Developed in collaboration with Tasso Inc, a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient focused logistics and cutting-...

Read More

Cell and Gene Therapy

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

news image

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

news image

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More
news image

Cell and Gene Therapy

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More
news image

Cell and Gene Therapy

Q² SOLUTIONS LAUNCHES INNOVATIVE SELF-COLLECTION SAFETY LAB PANEL IN COLLABORATION WITH TASSO

Q² Solutions and IQVIA, Tasso | October 07, 2022

Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory. Developed in collaboration with Tasso Inc, a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient focused logistics and cutting-...

Read More
news image

Cell and Gene Therapy

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More
news image

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More